Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 28, p.4741-6 (2009)

Keywords:

Acute Disease, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Neoplastic, Humans, Idarubicin, Leukemia, Myeloid, Male, Middle Aged, Oligonucleotides, Peripheral Nervous System Diseases, RECURRENCE, Reverse Transcriptase Polymerase Chain Reaction, RNA, Messenger, Treatment Outcome, X-Linked Inhibitor of Apoptosis Protein

Abstract:

X-linked inhibitor of apoptosis protein (XIAP) is an inhibitor of caspases 3 and 9 which are overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance. We report on a phase I/II trial of the XIAP antisense oligonucleotide AEG35156 in combination with reinduction chemotherapy.